FOSTER CITY, Calif. — November 20, 2025 — Leads & Copy — Apollomics Inc. (Nasdaq: APLM) has reached a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (collectively, “TWVC”), resolving a legal dispute that originated in the Grand Court of the Cayman Islands.
The settlement agreement, involving entities represented by Triwise Capital Management Ltd, addresses claims made by minority shareholders regarding the redemption of preferred shares before Apollomics’ merger with Maxpro Capital Acquisition Corporation in 2023. The litigation, filed in the Cayman Islands, is now set to be dismissed pending court approval of the settlement.
Under the agreement, Apollomics will pay TWVC a total of $5 million in cash, distributed in installments over two years, along with approximately $879,757.78 to cover associated legal expenses. In return, TWVC will withdraw all claims against Apollomics and its affiliates. The settlement concludes the Cayman Litigation, which initially sought approximately US$40 million in damages, according to Apollomics’ Form 20-F filed in April 2025.
Apollomics is a biopharmaceutical company focused on oncology therapies. Their lead program, vebreltinib (APL-101), is a c-Met inhibitor being evaluated in a Phase 2 clinical trial for non-small cell lung cancer and other advanced tumors.
The company has cautioned that forward-looking statements in the press release are subject to risks, uncertainties, and other factors outlined in their annual report on Form 20-F and other SEC filings.
Apollomics does not plan to update any forward-looking statements unless required by law.
Peter Lin can be contacted at Peter.lin@apollomicsinc.com.
Source: Apollomics Inc.
